Literature DB >> 15683116

A case of pseudomembranous colitis associated with rifampin.

Ji Young Park1, Joon Seok Kim, Sun Jong Jeung, Myung Sook Kim, Seok Chan Kim.   

Abstract

Pseudomembranous colitis is known to develop with long-term antibiotic administration, but antitubercular agents are rarely reported as a cause of this disease. We experienced a case of pseudomembranous colitis associated with rifampin. The patient was twice admitted to our hospital for the management of frequent bloody, mucoid, jelly-like diarrhea and lower abdominal pain that developed after antituberculosis therapy that included rifampin. Sigmoidoscopic appearance of the rectum and sigmoid colon and mucosal biopsy were compatible with pseudomembranous colitis. The antitubercular agents were discontinued and metronidazole was administered orally. The patient's symptoms were resolved within several days. The antituberculosis therapy was changed to isoniazid, ethambutol and pyrazinamide after a second bout of colitis. The patient had no further recurrence of diarrhea and abdominal pain. We report here on a case of pseudomembranous colitis associated with rifampin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15683116      PMCID: PMC4531579          DOI: 10.3904/kjim.2004.19.4.261

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  15 in total

1.  Colitis due to antituberculous chemotherapy.

Authors:  M M Huycke; J D Leu; M A Jacocks; R T Guild; R Whang
Journal:  South Med J       Date:  1991-02       Impact factor: 0.954

2.  Rifampicin-associated pseudomembranous colitis.

Authors:  A Nakajima; S Yajima; T Shirakura; T Ito; Y Kataoka; K Ueda; D Nagoshi; H Kanemoto; N Matsuhashi
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

Review 3.  Delayed onset of pseudomembranous colitis after rifampin therapy.

Authors:  R P Byrd; T M Roy; M A Ossorio; C L Fields
Journal:  South Med J       Date:  1997-06       Impact factor: 0.954

4.  Pseudomembranous colitis probably due to rifampicin.

Authors:  G Fournier; J Orgiazzi; B Lenoir; M Dechavanne
Journal:  Lancet       Date:  1980-01-12       Impact factor: 79.321

Review 5.  Pseudomembranous colitis: causes and cures.

Authors:  C M Surawicz; L V McFarland
Journal:  Digestion       Date:  1999 Mar-Apr       Impact factor: 3.216

Review 6.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

7.  [Pseudomembranous rectocolitis and rifampicin].

Authors:  C Seigneuric; M Plantavid; J L Laborie; S Vancina; J L Rumeau; J Lemozy
Journal:  Gastroenterol Clin Biol       Date:  1982-03

8.  Rifampicin-associated pseudomembranous colitis.

Authors:  S P Boriello; R H Jones; I Phillips
Journal:  Br Med J       Date:  1980-11-01

9.  Non-antibiotic therapy for Clostridium difficile infection.

Authors:  Subhas Banerjee; J. Thomas Lamont
Journal:  Curr Opin Infect Dis       Date:  2000-06       Impact factor: 4.915

10.  Pseudomembranous colitis in a patient on rifampicin and ethambutol.

Authors:  H J Moriarty; B A Scobie
Journal:  N Z Med J       Date:  1980-04-23
View more
  2 in total

1.  Rifampin-induced Pseudomembranous Colitis with Rectosigmoid Sparing.

Authors:  Sun Young Yim; Ja Seol Koo; Ye Ji Kim; Sang Jung Park; Jin Nam Kim; Sung Woo Jung; Hyung Joon Yim; Sang Woo Lee; Jai Hyun Choi; Chang Duck Kim
Journal:  Clin Endosc       Date:  2011-12-31

2.  Incidence and Clinical Outcomes of Clostridium difficile Infection after Treatment with Tuberculosis Medication.

Authors:  Yu Mi Lee; Kyu Chan Huh; Soon Man Yoon; Byung Ik Jang; Jeong Eun Shin; Hoon Sup Koo; Yunho Jung; Sae Hee Kim; Hee Seok Moon; Seung Woo Lee
Journal:  Gut Liver       Date:  2016-03       Impact factor: 4.519

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.